Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +51.10%
#3 Cysic Cysic +41.67%
#4 Glidr Glidr +36.41%
#5 Walrus Walrus +29.37%
#6 Humanity Humanity +23.38%
#7 Enso Enso +16.32%
#8 Codatta Codatta +15.99%
#9 Tutorial Tutorial +15.81%
#10 Ribbita by Virtuals Ribbita by Virtuals +14.43%
Coin of the day
EXOD EXOD
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Limited

ASLN
Rang in Aktien #37031
ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the... ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the clinical stage, primarily focused on immunology, and dedicated to creating innovative treatments that profoundly enhance patients' lives. Its advanced therapeutic pipeline features ASLAN004, a monoclonal antibody currently being evaluated for atopic dermatitis and a range of other immunological disorders. Also under development is ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase, intended to treat autoimmune conditions. The company is involved in a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd., aimed at pioneering immuno-oncology therapeutics that target the AhR pathway. Furthermore, ASLAN maintains partnerships with various entities, including Almirall, Array BioPharma, and CSL Limited. Established in 2010, the company's headquarters are located in Singapore.
Aktienkurs
$0.6
Zuletzt synchronisiert: 2024-08-14
Marktkapitalisierung
$2.09M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
SG
Handel ASLAN Pharmaceuticals Limited (ASLN)

Kategorie

Healthcare
P/S-Verhältnis für ASLAN Pharmaceuticals Limited (ASLN)
P/S-Verhältnis zum August 2026 TTM: 64.76
Laut den neuesten Finanzberichten und dem Aktienkurs von ASLAN Pharmaceuticals Limited beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 64.76. Am Ende des Jahres 2022 lag das P/S-Verhältnis bei 0.00.
P/S-Verlauf für ASLAN Pharmaceuticals Limited von 2014 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
2026 (TTM) 64.76 28,056.61%
2023 0.23 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 -100.00%
2019 7.03 0.00%
2018 0.00 0.00%
2017 0.00 -100.00%
2016 4.07 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -84.30%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -84.36%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.74 -92.68%
BE